Altshuler Shaham’s Antares Pharma, Inc. ATRS Stock Holding History

Altshuler Shaham’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-24,404	Closed	-$100K	–	770
2021 Q1	$100K	Buy	+24,404	New	+$106K	﹤0.01%	220
2020 Q1	–	Sell	-2,862	Closed	-$13K	–	644
2019 Q4	$13K	Buy	+2,862	New	+$11.7K	﹤0.01%	317

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

Altshuler Shaham's ATRS Position: Q2 2021 in Review

Altshuler Shaham sold out of Antares Pharma, Inc. (ATRS) in Q2 2021, closing a stake of 24,404 shares — an estimated $100K sold.

Altshuler Shaham first reported a position in ATRS in Q4 2019 and held it in 2 quarters. The position peaked at $100K in Q1 2021. 175 funds tracked by Wall St. Rank hold ATRS as of Q2 2021.

Altshuler Shaham reported no remaining Antares Pharma, Inc. position as of Q2 2021 after selling out during the quarter.
Altshuler Shaham sold 24,404 Antares Pharma, Inc. shares in Q2 2021, an estimated $100K.
Altshuler Shaham first reported a position in Antares Pharma, Inc. in Q4 2019 and held it in 2 quarters.
Altshuler Shaham's Antares Pharma, Inc. position peaked at $100K in Q1 2021.
175 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2021.

Based on Altshuler Shaham's 13F filing for Q2 2021, filed 16 Aug 2021.